D-JNKI-1

a synthetic, cell permeable peptide that blocks the MAPK-JNK signal pathway; has potential therapeutic value for long-term protection of both the morphological integrity and physiological function of the organ of Corti during times of oxidative stress

Also Known As:

Networked: 52 relevant articles (6 outcomes, 12 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Bonny, Christophe: 10 articles (07/2010 - 07/2004)
2.	Borsello, Tiziana: 7 articles (12/2021 - 01/2006)
3.	Ji, Ru-Rong: 6 articles (02/2018 - 03/2006)
4.	Meyer, Thomas: 5 articles (01/2019 - 04/2007)
5.	Hirt, Lorenz: 5 articles (04/2012 - 07/2004)
6.	Eshraghi, Adrien A: 4 articles (10/2018 - 06/2006)
7.	Behar-Cohen, Francine: 4 articles (02/2017 - 09/2010)
8.	Combette, Jean-Marc: 4 articles (02/2017 - 09/2010)
9.	Deloche, Catherine: 4 articles (02/2017 - 09/2010)
10.	Van De Water, Thomas R: 4 articles (03/2013 - 12/2004)

Related Diseases

1.	Tinnitus 09/01/2014 - "In severe-to-profound ASNHL patients (threshold ≥60 dB), AM-111 0.4 mg/ml showed statistically significant, clinically relevant, and persistent improvements in hearing and speech discrimination and higher tinnitus remission compared with placebo. " 09/01/2014 - "Single-dose intratympanic injection of AM-111 (0.4 or 2.0 mg/ml) or placebo; optionally, oral prednisolone if hearing improvement was less than 10 dB at Day 7. Efficacy was assessed by absolute hearing improvement (primary end point, Day 7), percentage hearing improvement, complete hearing recovery, speech discrimination improvement, and complete tinnitus remission. " 01/01/2019 - "Single-dose intratympanic injection of AM-111 (0.4 or 0.8 mg/ml) or placebo; oral prednisolone as reserve therapy if hearing improvement < 10 dB at Day 7. Hearing improvement to Day 28 was the primary efficacy endpoint; complete hearing recovery, frequency of reserve therapy used, complete tinnitus remission, improvement in word recognition were secondary endpoints. "
2.	Hearing Loss (Hearing Impairment) 01/01/2010 - "AM-111 prevents hearing loss from SC transection in the guinea pig model of PA-OM." 12/01/2011 - "Direct application of AM-111 in gel formulation on the round window was effective in preventing acute hearing loss because of transient cochlear ischemia." 01/01/2010 - "The goal of this study was to determine if round window application of AM-111 following SC transection in the presence of Pseudomonas aeruginosa otitis media (PA-OM) may reduce the associated hearing loss. " 01/01/2010 - "AM-111, an apoptosis inhibitor, has been shown to mitigate hearing loss resulting from a variety of inner ear injuries. " 01/01/2010 - "AM-111 prevents hearing loss from semicircular canal injury in otitis media."
3.	Noise-Induced Hearing Loss (Acoustic Trauma) 09/01/2007 - "For the first application of AM-111 in humans, we organized a clinical phase I/II trial in patients with acute acoustic trauma after exposure to firecrackers in Berlin and Munich on New Year's Eve 2005/2006. " 09/17/2003 - "Local delivery of D-JNKI-1 also prevented acoustic trauma-induced permanent hearing loss in a dose-dependent manner. " 10/01/2018 - "When compared to untargeted nanoparticles, the delivery of a c-Jun N-terminal kinase (JNK) inhibitor, D-JNKi-1, to OHCs by targeted nanoparticles improved protection from noise induced hearing loss (NIHL). "
4.	Ischemia 01/01/2008 - "Addition of rtPA after ischemia enhanced the ischemic damage both in vitro and in vivo, but XG-102 was still able to induce a significant neuroprotection. " 01/01/2008 - "XG-102 was injected intravenously in a single dose, 6 h after ischemia. " 04/01/2007 - "d-JNKI-1 delivered before onset of ischemia prevented the increase in JNK activity while not affecting ERK1/2 and p38-MAPK activation. " 01/01/2008 - "A single intravenous administration of XG-102 several hours after ischemia induces a powerful neuroprotection. " 12/01/2011 - "Direct application of AM-111 in gel formulation on the round window was effective in preventing acute hearing loss because of transient cochlear ischemia."
5.	Cognitive Dysfunction 06/01/2013 - "When phosphorylated tau (AT8 epitope) was analyzed a significant reduction was observed in the hippocampus of D-JNKI-1 treated SAMP8 mice, providing a plausible explanation for the attenuation of cognitive decline shown by these animals. "

Related Drugs and Biologics

1.	Prednisolone (Predate)
2.	JNK Mitogen-Activated Protein Kinases
3.	DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)
4.	Epitopes
5.	Peptides (Polypeptides)
6.	Neomycin
7.	Endotoxins
8.	Therapeutic Uses
9.	Dextran Sulfate
10.	Dexamethasone (Maxidex)

Related Therapies and Procedures

1.	Intratympanic Injection
2.	Therapeutics
3.	Aftercare (After-Treatment)
4.	Intravenous Administration
5.	Resuscitation